12 completed, 4 terminated, 1 withdrawn. 10 Phase 2, 7 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Terminated 3, Withdrawn 1 |
| Phase 3 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
Follow fasinumab: new trials by email Literature Review of fasinumab trials Research Report on fasinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip Fasinumab, Naproxen, Diclofenac - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | Terminated | Regeneron Pharmaceuticals | 23 | 2019-04-08 | 2023-10-17 |
| To Assess the Patients' Ability to Self-Administer Fasinumab Fasinumab AI, Fasinumab PFS - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 1 | Completed | Regeneron Pharmaceuticals | 100 | 2019-01-23 | 2021-03-03 |
| Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee Fasinumab, Placebo - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | Completed | Regeneron Pharmaceuticals | 180 | 2018-10-15 | 2023-03-01 |
| Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee Fasinumab, Placebo - Chronic Low Back Pain, Osteoarthritis | Phase 3 | Terminated | Regeneron Pharmaceuticals | 63 | 2017-10-30 | 2021-06-30 |
| Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip Fasinumab, Diclofenac, Celecoxib - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 3 | Completed | Regeneron Pharmaceuticals | 1650 | 2017-10-26 | 2023-02-24 |
| Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain MT-5547, MT-5547-matching placebo - Osteoarthritis, Knee / Osteoarthritis, Hip | Phase 2 / Phase 3 | Completed | Tanabe Pharma Corporation | 626 | 2017-09-08 | 2026-01-07 |
| A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip Fasinumab, Naproxen, Fasinumab-matching placebo - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 3 | Completed | Regeneron Pharmaceuticals | 3307 | 2017-08-17 | 2022-11-14 |
| Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip Fasinumab, Placebo - Osteoarthritis of the Knee or Hip | Phase 3 | Completed | Regeneron Pharmaceuticals | 5331 | 2016-02-17 | 2023-10-13 |
| A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain Fasinumab, placebo - Low Back Pain | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 563 | 2016-01-26 | 2020-06-16 |
| Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects Fasinumab, Placebo - Healthy Volunteers | Phase 1 | Completed | Regeneron Pharmaceuticals | 72 | 2015-07-01 | 2016-05-12 |
| Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip REGN475, Placebo - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 421 | 2015-05-01 | 2017-03-27 |
| Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain REGN475/SAR164877, Placebo (for REGN475/SAR164877) - Abdominal Pain Upper | Phase 2 | Terminated | Regeneron Pharmaceuticals | 15 | 2009-12-01 | 2013-05-27 |
| Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain REGN475/SAR164877, Placebo (for REGN475/SAR164877) - Back Pain | Phase 2 | Terminated | Regeneron Pharmaceuticals | 41 | 2009-11-01 | 2013-05-27 |
| A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain REGN475, Placebo Injection - Sciatica | Phase 2 | Completed | Regeneron Pharmaceuticals | 159 | 2009-11-01 | 2011-12-08 |
| A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee REGN475, Placebo - Osteoarthritis of the Knee | Phase 1 / Phase 2 | Completed | Regeneron Pharmaceuticals | 200 | 2009-08-01 | 2011-12-08 |
| A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects REGN475 (SAR164877) - Healthy | Phase 1 | Completed | Regeneron Pharmaceuticals | 56 | 2009-02-01 | 2012-05-10 |
| A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee REGN475, Placebo - Osteoarthritis | Phase 2 | Withdrawn | Regeneron Pharmaceuticals | 2015-03-18 |
Osteoarthritis, Knee (8) · Osteoarthritis, Hip (6) · Osteoarthritis (3) · Back Pain (2) · Low Back Pain (1) · Pain (1) · Sciatica (1)
Regeneron Pharmaceuticals (16) · Tanabe Pharma Corporation (1)
United States (15) · Poland (5) · United Kingdom (4) · Denmark (3) · Hungary (3) · Estonia (2) · Germany (2) · Lithuania (2) · Romania (2) · Russia (2) · South Africa (2) · Spain (2) · Ukraine (2) · Bulgaria (1) · Canada (1)
Paul J Tiseo, PhD (1) · Paul Tiseo, PhD (1)
PMID 39004211, PMID 41545313, PMID 31207169, PMID 40001000, PMID 41323020
2017 (3), 2015 (2), 2016 (1), 2018 (1)